Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Drug Resistance Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for YES1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YES1 Active Kinase Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View YES1 Products |
| Gene Delivery | YES1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View YES1 Products |
| Benchmark Ab | Anti-YES1 Antibody Recombinant positive control for assay validation. |
View YES1 Products |
| Validator | YES1 siRNA Set For knockdown verification. |
View YES1 Products |
| Related Target A | EGFR YES1 activation bypasses EGFR inhibition, driving acquired resistance to EGFR TKIs (e.g., osimertinib). |
View EGFR Products |
| Related Target B | SRC Closest Src family homolog; critical for counter-screening to ensure drug selectivity. |
View SRC Products |
| Related Target C | ERBB2 YES1 mediates resistance to HER2-targeted therapies in breast and gastric cancers. |
View ERBB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High homology within Src family (off-target toxicity screening) | Homolog panel proteins (SRC, FYN, LYN) strictly verified by mass spectrometry and sequence identity |
| In vitro kinase assay reproducibility and batch variation | High purity (>95%), theoretical MW verified, and endotoxin controlled for consistent enzymatic assays |
| Lack of controls for cellular pathway assays | Validated siRNA sets and high-titer Lentivirus particles for stable cell line construction |
Live YES1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for YES1 therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective YES1 small molecules and PROTACs (Proteolysis Targeting Chimeras). As first-generation multi-targeted SFK (Src Family Kinase) inhibitors like dasatinib face clinical limitations due to off-target toxicities (e.g., pleural effusion), the next wave of R&D is targeting highly selective YES1 degradation and combination strategies to overcome EGFR TKI resistance in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors | Oncolys BioPharma, Blueprint Medicines | NSCLC, Colorectal Cancer, Esophageal Cancer | Kinase Selectivity Assay (Need high-purity YES1 vs. SRC/FYN panels) |
| PROTAC / Degraders | Arvinas, Academic Consortia | TKI-Resistant Solid Tumors | Degradation kinetics and expression validation (Need Lentivirus for stable overexpressing lines) |
| Combination Therapies (EGFRi + YES1i) | AstraZeneca, clinical sponsors | EGFR-mutant TKI-resistant NSCLC | Bypass resistance modeling (Need sequence-verified EGFR & YES1 reagents) |